Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Zhang Y, Guo J, Chen W, Zhao L, Huang X. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation. Bone Marrow Transplant. 2023 Dec 26. https://doi.org/10.1038/s41409-023-02185-z.
2. Bianchi G, Kumar S. Systemic amyloidosis due to clonal plasma cell diseases. Hematol Oncol Clin North Am. 2020;34:1009–26. https://doi.org/10.1016/j.hoc.2020.08.001.
3. Administration U.S.F.D. FDA Grants Accelerated Approval to Darzalex Faspro for Newly Diagnosed Light Chain Amyloidosis. [(accessed on 15 January 2021)]. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-darzalex-faspro-newly-diagnosed-light-chain-amyloidosis.
4. Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015;33:1371–8. https://doi.org/10.1200/JCO.2014.57.4947.
5. Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31:4319–24. https://doi.org/10.1200/JCO.2013.50.8499.